Trial Profile
A prospectiv, multi-center, non-intervention study of Apatinib in the treatment of advanced gastric cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jan 2019
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Acronyms AHEAD-G203
- 18 Jun 2016 New trial record